First long-acting factor IX concentrate approved for patients with hemophilia B!

Alprolix is the first hemophilia B treatment designed to last longer in the circulation. It therefore requires less frequent injections when used to prevent or reduce the frequency of bleeding. The concentrate is approved to help control and prevent bleeding episodes and manage surgical bleeding, and may be used for prophylaxis. For more information, read the FDA announcement.

Did you like this? Share it: